CE Disclosures and Faculty Information

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of Hodgkin lymphoma.
  
  LEARNING OBJECTIVES

  • Consider disease- and patient-related factors, including age and comorbidities, stage and bulk of disease and International Prognostic Score, to guide the selection of first-line therapy for individuals with newly diagnosed classical Hodgkin lymphoma (HL).
  • Develop a long-term care plan for patients with relapsed/refractory HL, considering prior exposure to systemic therapy, eligibility for transplant, symptomatology, performance status and personal goals for treatment.
  • Review published research outlining the benefits and risks associated with various systemic therapies for patients at first relapse, and use this information to discern which of these may be appropriate as a bridge to referral for autologous stem cell transplant (ASCT).
  • Appreciate available data documenting the efficacy of consolidation therapy after ASCT, and use this knowledge to identify patients appropriate for this approach.
  • Evaluate the biologic rationale for and published clinical research findings with anti-PD-1 antibodies combined with other systemic therapies (eg, biologic agents, chemotherapy) and assess the potential current and future role of this strategy for patients with newly diagnosed or relapsed/refractory HL.
  • Recall ongoing trials investigating novel agents and strategies for the treatment of HL, and counsel appropriately selected patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Research To Practice designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, complete the Post-test with a score of 100% and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/OncologyTodayHL21/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Andrew M Evens, DO, MSc
  Associate Vice Chancellor, Clinical Innovation and Data Analytics
  Rutgers Biomedical and Health Sciences, Rutgers University
  Associate Director (Clinical Services), Rutgers Cancer Institute of New Jersey
  Professor of Medicine, Rutgers Robert Wood Johnson Medical School
  System Director of Medical Oncology, and Oncology Lead for the Combined Medical Group, RWJBarnabas Health
  New Brunswick, New Jersey
  
  Advisory Committee: Epizyme Inc, HUTCHMED, Karyopharm Therapeutics, Miltenyi Biotec, MorphoSys, Pharmacyclics LLC, an AbbVie Company, Seagen Inc; Consulting Agreements: COTA, Curio Science, Patient Power; Data and Safety Monitoring Board/Committee: AbbVie Inc, Novartis, Pharmacyclics LLC, an AbbVie Company.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from Seagen Inc.
  
  Release date: December 2021
  Expiration date: December 2022
  
  After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.